Comparison of repaglinide and glimepiride in type 2 diabetes: combination with DPP-4 inhibitors, vildagliptin and linagliptin
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
Price : $35 *
At a glance
- Drugs Glimepiride (Primary) ; Repaglinide (Primary) ; Linagliptin; Vildagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Apr 2015 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 18 Oct 2013 Planned end date added (31 Mar 2017) as reported by University Hospital Medical Information Network - Japan.
- 12 Apr 2013 New trial record